The BLMH Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, in which the BLMH gene has been disruptively modified to abrogate its expression. This product provides a reliable loss-of-function model for probing the cellular functions of the BLMH cysteine protease and its roles in drug detoxification and peptide metabolism within a non-small cell lung cancer (NSCLC) epithelial background.
The parental A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male and is widely adopted as an in vitro model for NSCLC and drug metabolism studies. These adherent epithelial cells exhibit robust growth and retain key metabolic pathways, making them particularly suitable for investigating the pharmacokinetic determinants of chemotherapeutic agent response and toxicity.
BLMH encodes a cytosolic cysteine protease that mediates the deamidation and hydrolysis of bleomycin, thereby inactivating this chemotherapeutic glycopeptide and contributing to inherent or acquired drug resistance. The enzyme is transcriptionally regulated by NRF2 in response to oxidative stress or direct bleomycin challenge, and its catalytic activity is essential for the processing of homocysteine-thiolactone to homocysteine, as well as for the degradation of amyloid-beta peptides. BLMH forms functional complexes with ubiquitin and interacts with amyloid precursor protein, positioning it at the interface of drug metabolism, proteostasis, and neuroinflammatory peptide handling. In the knockout setting, loss of BLMH activity leads to intracellular accumulation of bleomycin, reduced homocysteine-thiolactone hydrolysis, and impaired amyloid-beta clearance, thereby shifting the cellular balance toward enhanced drug sensitivity and altered proteostatic control.
In the A-549 NSCLC context, BLMH deletion produces a pronounced hypersensitivity to bleomycin, unlocking applications for mechanistic dissection of chemoresistance pathways and the preclinical evaluation of BLMH inhibitors as potential chemosensitizers. Beyond oncology, this model enables the study of epithelial cell-intrinsic mechanisms of homocysteine metabolism and amyloid-beta turnover, which are processes linked to systemic homocystinuria and Alzheimer??s disease pathology. The polyclonal nature of the knockout population retains the genetic heterogeneity of the parental line while uniformly disrupting target gene function, thus providing a physiologically relevant backdrop for drug response profiling.
Typical experimental uses include bleomycin cytotoxicity assays (IC50 determination) and apoptosis readouts to quantify the functional consequences of BLMH loss, as well as western blotting and immunofluorescence to confirm target disruption at the protein level. Fluorometric protease activity assays using synthetic substrates can directly verify the absence of BLMH enzymatic function, and mass spectrometry-based peptidomics may reveal alterations in endogenous peptide cleavage products such as amyloid-beta species. These cells are also well suited for co-treatment studies with oxidative stress inducers and NRF2 modulators to explore upstream regulatory circuitry. For additional technical details, lot-specific validation data, or to discuss custom gene editing projects, please contact Ascent Research.
